Haywood Miller - Emergent Biosolutions Interim Officer

EBS Stock  USD 10.11  0.08  0.80%   

Executive

Haywood Miller is Interim Officer of Emergent Biosolutions
Address 400 Professional Drive, Gaithersburg, MD, United States, 20879
Phone240 631 3200
Webhttps://www.emergentbiosolutions.com

Emergent Biosolutions Management Efficiency

The company has Return on Asset of (0.0422) % which means that on every $100 spent on assets, it lost $0.0422. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3464) %, meaning that it generated no profit with money invested by stockholders. Emergent Biosolutions' management efficiency ratios could be used to measure how well Emergent Biosolutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.57 in 2024. Return On Capital Employed is likely to gain to -0.59 in 2024. At this time, Emergent Biosolutions' Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 231 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 799.2 M in 2024.
Emergent Biosolutions has 860.2 M in debt with debt to equity (D/E) ratio of 0.56, which is OK given its current industry classification. Emergent Biosolutions has a current ratio of 3.84, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Emergent to invest in growth at high rates of return.

Similar Executives

Showing other executives

EXECUTIVE Age

Jiny MBABausch Health Companies
47
Bjorn TimelinHaleon plc
N/A
Bjarne TellmannHaleon plc
57
Donald PearlBausch Health Companies
N/A
Aimee LenarBausch Health Companies
N/A
Cees HeimanBausch Health Companies
N/A
Franck RiotHaleon plc
56
JeanJacques CharhonBausch Health Companies
59
Ed PetterHaleon plc
N/A
William WoodfieldBausch Health Companies
N/A
Claire DicksonHaleon plc
N/A
Namrata PatelHaleon plc
58
Arthur ShannonBausch Health Companies
N/A
Willie MDIntracellular Th
N/A
Josh CoyleBausch Health Companies
N/A
Karen EsqIntracellular Th
62
Seana CarsonBausch Health Companies
51
Tobias HestlerHaleon plc
52
Line DeckerHaleon plc
50
Kathleen FitzpatrickBausch Health Companies
N/A
Adrian MorrisHaleon plc
57
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Emergent Biosolutions operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 2416 people. Emergent Biosolutions (EBS) is traded on New York Stock Exchange in USA. It is located in 400 Professional Drive, Gaithersburg, MD, United States, 20879 and employs 1,600 people. Emergent Biosolutions is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Emergent Biosolutions Leadership Team

Elected by the shareholders, the Emergent Biosolutions' board of directors comprises two types of representatives: Emergent Biosolutions inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Emergent. The board's role is to monitor Emergent Biosolutions' management team and ensure that shareholders' interests are well served. Emergent Biosolutions' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Emergent Biosolutions' outside directors are responsible for providing unbiased perspectives on the board's policies.
Kelly Warfield, Senior Development
Sean Kirk, Executive Vice President - Manufacturing and Technical Operations
William Hartzel, Senior Bioservices
Robert Burrows, IR Contact Officer
Stephanie Duatschek, Chief VP
Sue Bailey, Independent Director
Jerome Hauer, Independent Director
Haywood Miller, Interim Officer
Kathryn Zoon, Independent Director
Seamus Mulligan, Director
George Joulwan, Independent Director
Karen Smith, Executive Vice President Chief Medical Officer
Paul Williams, Senior Business
Keith Katkin, Independent Director
Jessica Perl, Corporate Counsel
Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer
Richard MBA, CFO VP
Jennifer Fox, Executive Vice President - External Affairs, General Counsel, Corporate Secretary
Katherine Strei, Executive Vice President - Human Resources and Communications, Chief Human Resources Officer
Michelle Pepin, Senior Officer
Fuad ElHibri, Executive Chairman of the Board
Coleen Glessner, Executive Compliance
Lynn Kieffer, VP Communications
Joseph Papa, CEO President
Marvin White, Director
Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary
Robert Sr, Pres CEO
Adam Havey, Executive VP and President of Biodefense Division
Louis Sullivan, Independent Director
Ronald Richard, Lead Independent Director
Zsolt Harsanyi, Non-Executive Independent Chairman of the Board
Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer

Emergent Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Emergent Biosolutions a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Emergent Stock Analysis

When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.